ATE250427T1 - Zusammensetzungen und deren verwendung zur hemmung von angiogenese - Google Patents

Zusammensetzungen und deren verwendung zur hemmung von angiogenese

Info

Publication number
ATE250427T1
ATE250427T1 AT99954789T AT99954789T ATE250427T1 AT E250427 T1 ATE250427 T1 AT E250427T1 AT 99954789 T AT99954789 T AT 99954789T AT 99954789 T AT99954789 T AT 99954789T AT E250427 T1 ATE250427 T1 AT E250427T1
Authority
AT
Austria
Prior art keywords
methods
angiogenesis
compositions
inhibiting angiogenesis
cell proliferation
Prior art date
Application number
AT99954789T
Other languages
English (en)
Inventor
Michael S O'reilly
Steven Pirie-Shepherd
M Judah Folkman
Original Assignee
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Medical Center filed Critical Childrens Hosp Medical Center
Application granted granted Critical
Publication of ATE250427T1 publication Critical patent/ATE250427T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99954789T 1998-10-08 1999-10-08 Zusammensetzungen und deren verwendung zur hemmung von angiogenese ATE250427T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10352698P 1998-10-08 1998-10-08
US11613199P 1999-01-15 1999-01-15
PCT/US1999/023450 WO2000020026A2 (en) 1998-10-08 1999-10-08 Compositions and methods for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
ATE250427T1 true ATE250427T1 (de) 2003-10-15

Family

ID=26800564

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99954789T ATE250427T1 (de) 1998-10-08 1999-10-08 Zusammensetzungen und deren verwendung zur hemmung von angiogenese

Country Status (8)

Country Link
US (2) US6607724B2 (de)
EP (1) EP1117428B1 (de)
JP (1) JP2002526418A (de)
AT (1) ATE250427T1 (de)
AU (1) AU768076B2 (de)
CA (1) CA2344613A1 (de)
DE (1) DE69911629D1 (de)
WO (1) WO2000020026A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
ES2299425T3 (es) * 1999-05-13 2008-06-01 Gtc Biotherapeutics, Inc. Antitrombina iii producida geneticamente y formas mutantes de la misma.
DE19937656A1 (de) * 1999-08-13 2001-02-15 Aventis Behring Gmbh Verwendung von Antithrombin III zur Prophylaxe und Therapie von Erkrankungen
AU2001245734A1 (en) * 2000-03-15 2001-09-24 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
DE10102048A1 (de) * 2001-01-17 2002-07-18 Aventis Behring Gmbh Antithrombin III gegen durch Angiogenese verursachte Krankheiten
DE10159556A1 (de) * 2001-12-05 2003-06-12 Aventis Behring Gmbh Intellect Antithrombin III zur Präventation und Therapie vaskuloproliferativer Erkrankungen
DE10160133A1 (de) * 2001-12-07 2003-06-26 Transmit Technologietransfer Verwendung von koagulationsaktivem Antithrombin III zur Therapie von Angiogenese-abhängigen Erkrankungen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087415A (en) 1976-06-09 1978-05-02 William L. Wilson Antithrombin III
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
DE3426903A1 (de) 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
US5151509A (en) * 1988-12-16 1992-09-29 United States Of America Gene encoding serine protease inhibitor
DE3901917A1 (de) 1989-01-24 1990-07-26 Behringwerke Ag Mutanten von humanem antithrombin iii
US5319072A (en) 1992-01-10 1994-06-07 Alpha Therapeutic Corporation Human antithrombin-III preparation
JP3479539B2 (ja) 1992-04-10 2003-12-15 エーザイ株式会社 ヒトアンチトロンビンｉｉｉ変異体
US5589516A (en) 1993-04-05 1996-12-31 The Green Cross Corporation Liquid preparation of antithrombin-III and stabilizing method therefor
CN1275050A (zh) * 1997-08-15 2000-11-29 路德维格癌症研究所 内皮蛋白酶解活性和/或血管生成活性的刺激、调节和/或抑制

Also Published As

Publication number Publication date
CA2344613A1 (en) 2000-04-13
EP1117428B1 (de) 2003-09-24
US6607724B2 (en) 2003-08-19
US20030203838A1 (en) 2003-10-30
EP1117428A2 (de) 2001-07-25
JP2002526418A (ja) 2002-08-20
WO2000020026A3 (en) 2000-09-08
US20020076413A1 (en) 2002-06-20
AU768076B2 (en) 2003-12-04
WO2000020026A2 (en) 2000-04-13
DE69911629D1 (de) 2003-10-30
AU1105100A (en) 2000-04-26

Similar Documents

Publication Publication Date Title
ATE230394T1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
AU2002305450A1 (en) Proteomimetic compounds and methods
ATE362766T1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
BRPI0015533B8 (pt) enzima alfa-l-iduronidase humana recombinante, composição farmacêutica compreendendo a mesma e método para sua purificação
ATE435199T1 (de) Diarylharnstoffderivate und deren verwendung als chloridkanalblocker
AU2275397A (en) Troponin subunits and fragments useful as angiogenesis inhibitors
MX9803851A (es) Compuestos macrociclicos novedosos como inhibidores de metaloproteasas.
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
ATE250427T1 (de) Zusammensetzungen und deren verwendung zur hemmung von angiogenese
MXPA05005314A (es) Compuestos de lapacona novedosos y metodos de uso de los mismos.
WO1999009000A3 (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
DE69735545D1 (de) Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors
GB9924957D0 (en) Novel treatment
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
DE69934987D1 (de) Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen
ATE230414T1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
ATE211482T1 (de) Selektive inhibitoren des faktors x, eine azepinonstruktur enthaltend
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
DE60106604D1 (de) Verwendung von aloe-emodin zur behandlung von neuroektodermalen tumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties